U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date
Related news for (FOLD)
- Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
- Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
- Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
- 24/7 Market News Snapshot 17 October, 2024 – Amicus Therapeutics, Inc (NASDAQ:FOLD)